The differential effects of co-treatment with KYA1797K and cetuximab on the growth of CRC cells, which are dependent upon the mutational status of KRAS, were also observed in a dose-dependent manner in WT KRAS D-WT and DiFi cells but not in the KRAS-mutated D-MT and SW480 cells (Fig. 3d). The gene discussed is KRAS; the disease is colorectal carcinoma.